A phase I study of a novel taxane, TL310, orally administered every week in patients (pts) with advanced solid tumors No significant financial relationships to disclose. This is an ASCO Meeting ...
Glucarpidase treatment significantly improves kidney recovery odds and reduces risks of neutropenia and transaminitis in MTX-AKI patients. The study utilized a target trial emulation framework to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results